BR112012030359A2 - cepas probióticas para uso no aperfeiçoamento do sistema nervoso entérico - Google Patents

cepas probióticas para uso no aperfeiçoamento do sistema nervoso entérico

Info

Publication number
BR112012030359A2
BR112012030359A2 BR112012030359A BR112012030359A BR112012030359A2 BR 112012030359 A2 BR112012030359 A2 BR 112012030359A2 BR 112012030359 A BR112012030359 A BR 112012030359A BR 112012030359 A BR112012030359 A BR 112012030359A BR 112012030359 A2 BR112012030359 A2 BR 112012030359A2
Authority
BR
Brazil
Prior art keywords
nervous system
improving
enteric nervous
probiotic strains
enteric
Prior art date
Application number
BR112012030359A
Other languages
English (en)
Other versions
BR112012030359B1 (pt
Inventor
Biliana Lesic
Gianfranco Grompone
Isabelle Chambaud
Marie-Christine Degivry
Michel Neunlist
Sandrine Capronnier
Sophie Legrain-Raspaud
Tamara Smokvina
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of BR112012030359A2 publication Critical patent/BR112012030359A2/pt
Publication of BR112012030359B1 publication Critical patent/BR112012030359B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

cepas probióticas para uso no aperfeiçoamento do sistema nervoso entérico. a presente invenção refere-se ao uso de bactérias do ácido láctico, para uso na modificação do sistema nervoso entérico e, mais particularmente, no tratamento e/ou prevenção de distúrbios intestinais tais como constipação e/ou doença do intestino irritável.
BR112012030359A 2010-05-28 2011-05-27 composição compreendendo pelo menos uma cepa de bactérias e método de seleção de cepas de bactérias BR112012030359B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2010/001534 WO2011148219A1 (en) 2010-05-28 2010-05-28 Probiotic strains for use in improving the enteric nervous system
PCT/IB2011/052344 WO2011148355A1 (en) 2010-05-28 2011-05-27 Probiotic strains for use in improving the enteric nervous system

Publications (2)

Publication Number Publication Date
BR112012030359A2 true BR112012030359A2 (pt) 2016-08-09
BR112012030359B1 BR112012030359B1 (pt) 2020-05-05

Family

ID=43302705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030359A BR112012030359B1 (pt) 2010-05-28 2011-05-27 composição compreendendo pelo menos uma cepa de bactérias e método de seleção de cepas de bactérias

Country Status (14)

Country Link
US (2) US9198940B2 (pt)
EP (2) EP2857027B1 (pt)
JP (1) JP5923492B2 (pt)
KR (1) KR101779832B1 (pt)
CN (1) CN103209698B (pt)
BR (1) BR112012030359B1 (pt)
CA (1) CA2800768C (pt)
EA (1) EA028015B1 (pt)
ES (2) ES2744274T3 (pt)
MX (1) MX345063B (pt)
PL (1) PL2575837T3 (pt)
PT (1) PT2575837E (pt)
WO (2) WO2011148219A1 (pt)
ZA (1) ZA201208977B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
EP2925333A1 (en) 2012-11-12 2015-10-07 Compagnie Gervais Danone Lactobacillus rhamnosus strain for reducing body fat accumulation
WO2014096901A1 (en) 2012-12-18 2014-06-26 Compagnie Gervais Danone Strain of bifidobacterium animalis ssp. animalis
FR3004621B1 (fr) 2013-04-19 2015-05-15 Gervais Danone Sa Souche de lactobacillus rhamnosus regulatrice du metabolisme lipidique
CN103898007B (zh) * 2014-02-21 2016-08-17 刘洛贤 一株有活性的双歧杆菌菌株
JP6402016B2 (ja) * 2014-12-10 2018-10-10 国立大学法人岐阜大学 神経機能改善剤
CA2983083A1 (en) * 2015-04-30 2016-11-03 Probiotical S.P.A. Use of antibiotics with specific therapeutic activities combined with the simultaneous use of lactobacilli and/or bifidobacteria with a non-transferable antibiotic resistance, having the same therapeutic indication
US9730969B2 (en) 2015-11-06 2017-08-15 Mead Johnson Nutrition Company Nutritional compositions for promoting gut barrier function and ameliorating visceral pain
CN116286509A (zh) * 2017-09-29 2023-06-23 庆熙大学校产学协力团 新型乳酸菌及其应用
CN108753670A (zh) * 2018-05-28 2018-11-06 西北工业大学 多功能复合微生态制剂纳米硒-重组表达血管活性肠肽-乳酸乳球菌及制备方法
KR102238519B1 (ko) * 2018-12-28 2021-04-13 (주)메디톡스 외래 단백질을 발현하는 미생물, 및 그의 용도
KR102635553B1 (ko) * 2018-12-28 2024-02-13 주식회사 리비옴 외래 단백질을 발현하는 미생물, 및 그의 용도
WO2021127164A1 (en) * 2019-12-17 2021-06-24 Metagenics, Inc. Multi-strain probiotic composition and its use
KR20210129516A (ko) 2020-04-20 2021-10-28 주식회사 리비옴 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도
KR102527953B1 (ko) * 2021-03-29 2023-05-03 주식회사 리비옴 외래 단백질을 발현하는 미생물, 및 그의 용도
CN113248520A (zh) * 2021-04-07 2021-08-13 浙江华显光电科技有限公司 一种有机化合物及使用该化合物的有机发光器件
WO2024080918A1 (en) * 2022-10-13 2024-04-18 Baylor College Of Medicine Secretin inducing bacteria

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07173188A (ja) * 1993-12-17 1995-07-11 Tsumura & Co 新規アリソールおよびアリソール類を有効成分とする脳機能改善剤
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
FR2795917B1 (fr) 1999-07-06 2001-08-31 Gervais Danone Sa Procede de preparation d'un produit lacte immunostimulant et ses applications
FR2811333B1 (fr) 2000-07-04 2003-01-10 Gervais Danone Sa Microorganismes ayant une action modulatrice de la glycosylation de surface des cellules intestinales et methode de selection desdits microorganismes
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
FR2875406B1 (fr) 2004-09-21 2007-01-05 Danisco Souche de lactobacillus acidophilus ayant des proprietes analgesiques au niveau du systeme gastro-intestinal
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
WO2007036230A1 (en) 2005-09-28 2007-04-05 Nordisk Rebalance A/S Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors
WO2007132359A2 (en) 2006-05-12 2007-11-22 Danisco A/S Composition containing lactobacillus sp. and a cannabinoid receptor and/or a opioid receptor agonist
CN101095698B (zh) * 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
WO2008064489A1 (en) 2006-12-01 2008-06-05 Mcmaster University Probiotics to inhibit inflammation
FR2921795B1 (fr) * 2007-10-03 2011-04-29 Gervais Danone Sa Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
PL2072053T3 (pl) 2007-12-21 2013-02-28 Gervais Danone Sa Sposób zmniejszania obwodu brzucha przez podawanie bakterii bifidobacterium
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
EA021890B1 (ru) * 2009-11-02 2015-09-30 Компани Жервэ Данон Способ предотвращения и/или лечения болезни воспаленного кишечника, язвенного колита и болезни крона
WO2011148220A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving transepithelial resistance

Also Published As

Publication number Publication date
EA201291441A1 (ru) 2013-05-30
EA028015B1 (ru) 2017-09-29
EP2857027B1 (en) 2019-06-12
EP2575837A1 (en) 2013-04-10
CN103209698A (zh) 2013-07-17
US20130195822A1 (en) 2013-08-01
US9198940B2 (en) 2015-12-01
ES2508566T3 (es) 2014-10-16
EP2857027A1 (en) 2015-04-08
PT2575837E (pt) 2014-10-01
ES2744274T3 (es) 2020-02-24
JP5923492B2 (ja) 2016-05-24
WO2011148355A1 (en) 2011-12-01
CA2800768C (en) 2020-07-21
WO2011148219A1 (en) 2011-12-01
CA2800768A1 (en) 2011-12-01
PL2575837T3 (pl) 2015-03-31
MX2012013834A (es) 2013-04-08
BR112012030359B1 (pt) 2020-05-05
CN103209698B (zh) 2015-09-02
JP2013528053A (ja) 2013-07-08
KR20140000620A (ko) 2014-01-03
ZA201208977B (en) 2014-04-30
MX345063B (es) 2017-01-16
EP2575837B1 (en) 2014-06-25
US20160045557A1 (en) 2016-02-18
KR101779832B1 (ko) 2017-09-19

Similar Documents

Publication Publication Date Title
BR112012030359A2 (pt) cepas probióticas para uso no aperfeiçoamento do sistema nervoso entérico
BR112012022755A2 (pt) composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
BR112012033212A2 (pt) uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica
MX2017010710A (es) Composición terapeútica y profiláctica producida por microbiota.
WO2015026235A3 (en) Production of probiotics by in vitro enrichment of beneficial microorganisms from human or animal microbiota
MX2021007008A (es) Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.
BR112012032778A2 (pt) "proteínas multiespecíficas e multivalentes"
IN2012DN02463A (pt)
BR112014025469A2 (pt) uso de bactérias probióticas no tratamento de infecções bacterianas e regeneração da pele, bem como composições compreendendo cepas das referidas bactérias
CA2813064C (en) Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
IN2012DN01638A (pt)
MX2011005527A (es) Uso de la bacteria de acido lactico para tratar o prevenir el eczema.
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
EA201290709A1 (ru) Устойчивые к фагам молочно-кислые бактерии для текстурирования пищевых продуктов
IN2012DN02471A (pt)
MY178905A (en) Prevention, treatment and diagnosis of p.gingivalis infection
CN107405369A8 (zh) 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法
BRPI1015472A2 (pt) métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
UA118339C2 (uk) Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
NZ597319A (en) A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EP2281871A4 (en) NEW MILKY ACID BACTERIUM WITH ANTIALLERGIC ACTIVITY, ANTIALLERIC, FOOD AND PHARMACEUTICAL COMPOSITION, EACH WITH THE MILKY ACID BACTERIUM, AND METHOD FOR PRODUCING ANTIALLY ENGINEERING
BR112012030363A2 (pt) linhagens probióticas para uso na melhoria da resistência transepitelial
BR112012017300A2 (pt) processo de para preparação de uma biomassa compreendendo plantaricina e usos da mesma no campo médico
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 35/747 (2015.01), A23C 9/123 (2006.01), A23L

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/05/2011, OBSERVADAS AS CONDICOES LEGAIS.